TY - JOUR
T1 - How to diagnose heart failure with preserved ejection fraction
T2 - The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
AU - Pieske, Burkert
AU - Tschöpe, Carsten
AU - De Boer, Rudolf A.
AU - Fraser, Alan G.
AU - Anker, Stefan D.
AU - Donal, Erwan
AU - Edelmann, Frank
AU - Fu, Michael
AU - Guazzi, Marco
AU - Lam, Carolyn S.P.
AU - Lancellotti, Patrizio
AU - Melenovsky, Vojtech
AU - Morris, Daniel A.
AU - Nagel, Eike
AU - Pieske-Kraigher, Elisabeth
AU - Ponikowski, Piotr
AU - Solomon, Scott D.
AU - Vasan, Ramachandran S.
AU - Rutten, Frans H.
AU - Voors, Adriaan A.
AU - Ruschitzka, Frank
AU - Paulus, Walter J.
AU - Seferovic, Petar
AU - Filippatos, Gerasimos
N1 - Publisher Copyright:
© 2019 Published on behalf of the European Society of Cardiology. All rights reserved.
PY - 2019/10/21
Y1 - 2019/10/21
N2 - Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e′), left ventricular (LV) filling pressure estimated using E/e′, left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.
AB - Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e′), left ventricular (LV) filling pressure estimated using E/e′, left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.
KW - HFpEF
KW - Heart failure
KW - biomarkers
KW - diagnosis
KW - echocardiography
KW - exercise echocardiography
KW - natriuretic peptides
UR - http://www.scopus.com/inward/record.url?scp=85073653518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073653518&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehz641
DO - 10.1093/eurheartj/ehz641
M3 - Review article
C2 - 31504452
AN - SCOPUS:85073653518
SN - 0195-668X
VL - 40
SP - 3297
EP - 3317
JO - European Heart Journal
JF - European Heart Journal
IS - 40
ER -